- Home
- RDCM vs HUMA Comparison
RDCM vs HUMA Comparison
Compare RDCM & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | HUMA |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6M | 165.7M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDCM | HUMA |
|---|---|---|
| Price | $10.30 | $0.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $14.00 | $1.85 |
| AVG Volume (30 Days) | 75.7K | ★ 3.2M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | N/A | $72.32 |
| Revenue Next Year | $6.56 | $518.79 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $0.47 |
| 52 Week High | $16.74 | $1.90 |
Technical Indicators
Market Signals| Indicator | RDCM | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 27.19 |
| Support Level | $10.07 | N/A |
| Resistance Level | $10.79 | $0.75 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 24.18 | 6.40 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.